Article

Signaling pathway evaluation of leading ATRi, PARPi and CDK7i cancer compounds targeting the DNA Damage Response using Causal Inference

2024-02-19

Abstract excerpt

<h4>Introduction: </h4> There are many cancer drugs in development which target the DNA damage response (DDR), following early successes of drugs such as olaparib. However, various challenges to the success of these inhibitors exist, including the emergence of resistance, the identification of appropriate biomarkers to identify patients who will respond to treatment, as well as the identification of combination th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 738fdaca-8acd-50cb-89bd-53e73d18e5cb
DOI: 10.1101/2024.02.15.580418

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Signaling pathway evaluation of leading ATRi, PARPi and CDK7i cancer compounds targeting the DNA Damage Response using Causal InferenceDOI 10.1101/2024.02.15.580418Read

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibSemantic proximity Read

Machine learning-based prediction of response to PARP inhibition across cancer typesSemantic proximity Read

Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cellsSemantic proximity Read

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor ResistanceSemantic proximity Read

A quantitative chemotherapy genetic interaction map reveals new factors associated with PARP inhibitor resistanceSemantic proximity Read

Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer.Semantic proximity Read

KICDB: A Causality-Oriented Multi-Omics Database for Kinase Inhibitor-Induced CardiotoxicitySemantic proximity Read

Interactive webtool for analyzing drug sensitivity and resistance associated with genetic signatures of cancer cell lines.Semantic proximity Read

Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analysesSemantic proximity Read

Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXsSemantic proximity Read

PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic StrategySemantic proximity Read

KICDB: A Causality-Oriented Multi-Omics Database for Kinase Inhibitor-Induced CardiotoxicitySemantic proximity Read